Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU2-36P (U2 small nuclear RNA 36, pseudogene) is a human genomic locus classified as a pseudogene of the U2 snRNA gene family. It is highly similar at the sequence level to active U2 snRNA genes, especially in the conserved 5′ region, but it is generally considered nonfunctional and truncated at the 3′ end[3]. U2 snRNAs themselves are components of the spliceosome machinery, essential for pre-mRNA splicing[2][4][5], but pseudogenes like RNU2-36P do not contribute to spliceosomal function. The presence of multiple pseudogenes in the U2 family reflects gene duplication and retrotransposition events over evolution, and these pseudogenes are typically not transcribed or processed like their active gene counterparts. No established role in disease or therapy has been reported for RNU2-36P.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on U2 small nuclear RNA 36, pseudogene (RNU2-36P).